Show Summary Details
Page of

Cancer immunology 

Cancer immunology
Cancer immunology

Herman Waldmann

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 10 August 2020

Until recently, the prospects for harnessing immune mechanisms to fight cancer were not encouraging. The advent of monoclonal antibodies, both as diagnostics and as probes for molecular function, have been important, while the identification of dendritic cells as a major intermediary between the antigen source and T-cell activation has been crucial. Major advances in molecular biology and the creation of mutant mice lacking defined gene products have pinpointed key molecules influencing immune function. Finally, many translational efforts in vaccination, autoimmune disease, and transplantation have enabled identification of hitherto undervalued mechanisms that the immune system uses to regulate itself. A fuller understanding of self-tolerance mechanisms, tumour antigens, and the tumour microenvironment has catalysed a wide range of novel therapeutic strategies and has also allowed a re-evaluation of mechanisms underlying the benefits of past chemotherapies.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.